Related Experiment Video

Updated: Aug 30, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Anastasia Stella Perpinia1, Nikolaos Kadoglou2, Maria Vardaka3

  • 1Department of Cardiology, "G. Gennimatas" General Hospital, 11527 Athens, Greece.

Pharmaceuticals (Basel, Switzerland)
|August 26, 2022
PubMed

Insights

Cancer therapies can harm the heart, causing cardiotoxicity. Prompt recognition and management of these cardiac complications are vital for patients with hematologic malignancies to ensure treatment success.

Area of Science:

  • Cardiology
  • Hematology
  • Oncology

Background:

  • Modern hematologic cancer treatments improve patient outcomes.
  • Anticancer drugs and stem cell transplantation can cause significant cardiovascular side effects.
  • Cardiotoxicity poses a threat to the efficacy of cancer therapies.

Purpose of the Study:

  • To review the clinical manifestations of cardiotoxicity in cancer patients.
  • To discuss preventive strategies against drug-induced heart problems.
  • To outline pharmaceutical management for cardiotoxicity in hematologic malignancies.

Main Methods:

  • Literature review of cardiotoxicity in hematologic malignancies.
  • Analysis of clinical manifestations and cardiac disorders.
  • Evaluation of preventive and therapeutic pharmaceutical interventions.

Main Results:

  • Cardiotoxicity presents with diverse cardiac disorders like heart failure and arrhythmias.
  • Early detection and intervention are crucial for managing cardiotoxicity.
  • Cardiovascular risk management is integral to cancer care.

Conclusions:

  • Cardiotoxicity is a significant concern in hematologic malignancies treatment.
  • Comprehensive understanding and management of cardiotoxicity are essential.
  • Integrated care strategies improve cardiovascular health in cancer patients.

Keywords:
anthracyclinesanticancer targeted therapiescardiotoxicityheart failureleukemialymphoma

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
27
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
43
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
29
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
65
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
38